Cardio-vascular
Refine Search
Pharmaceutical
French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and vaccines that could result in up to 18 new launches for the company between 2014-2020, at an IR Thematic Seminar on New Medicines in Boston, USA. 20 November 2014
Biotechnology
A retrospective analysis has shown that patients treated with Kynamro (mipomersen sodium) injection for a mean of two years had a significant reduction in major adverse cardiovascular events (MACE) compared to two years prior to therapy. 19 November 2014
Pharmaceutical
The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study sub-analyses showing that its investigational antidote idarucizumab reverses the effects of Pradaxa (dabigatran etexilate mesylate), on fibrin formation in healthy volunteers. 19 November 2014
Pharmaceutical
New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure with reduced ejection fraction (HFrEF), shows it can reduce the risk of sudden death by 20%. 18 November 2014
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial analysts on the progress against the company’s strategic priorities of achieving scientific leadership and returning to growth. 18 November 2014
Pharmaceutical
Pharma giant Merck & Co has announced that the study investigating LDL-cholesterol-lowering drug Vytorin (ezetimibe/simvastatin) – which combines simvastatin with the non-statin Zetia (ezetimibe) – has met its primary and secondary endpoints. 18 November 2014
Pharmaceutical
New research published in the New England Journal of Medicine shows that while dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, the benefits and risks of treatment beyond one year are still uncertain. 18 November 2014
Pharmaceutical
A new study part-funded by US pharma giant Merck & Co (NYSE: MRK) has found that mutations in a gene encoding the NPC1L1 protein are linked to reduced LDL cholesterol levels. The data could have ramifications for Merck’s cholesterol-lowering drug Zetia (ezetimibe). 14 November 2014
Biotechnology
Sweden’s Athera Biotechnologies, which is 65% owned by Karolinska Development, says that German family-owned pharma major Boehringer Ingelheim will not exercise the option agreement to license Athera’s cardiovascular antibody. 12 November 2014
Biotechnology
US biotech firm HemoShear and Janssen Research and Development plan to report data showing that a subset of compounds used to treat rheumatoid arthritis (RA) also suppress inflammation and have the potential to promote vascular health. 11 November 2014
Pharmaceutical
Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular in competing for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to research and consulting firm GlobalData. 11 November 2014
Pharmaceutical
ScinoPharm Taiwan and China’s Nanjing King-friend Biochemical Pharmaceutical (NKF) announced today the joint research and development of a new drug, Regadenoson. Given each company's strengths and expertise, both sides aim to exploit business opportunities in the Chinese market for new drugs. 10 November 2014
Pharmaceutical
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a review of Corlentor/Procoralan (ivabradine) and has made recommendations aimed at reducing the risk of heart problems. 9 November 2014
Biotechnology
Swiss chemical supplier Lonza and US biotech firm Celladon Corp have entered into an agreement providing for the future commercial production of Mydicar (AAV1/SERCA2a). 3 November 2014
Pharmaceutical
Pharming Group and Salix Pharmaceuticals have launched Ruconest (C1 esterase inhibitor) in the USA for the treatment of acute angioedema attacks in adult and adolescent hereditary angioedema patients. 3 November 2014
Pharmaceutical
A US Food and Drug advisory panel has voted in favor of the use of Japanese pharma major Daiichi Sankyo’s Savaysa (edoxaban), but there was some ambivalence over labelling. 3 November 2014
Pharmaceutical
In draft guidance published today, the UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has recommended German family-owned pharma major Boehringer Ingelheim’s anti-blood clotting drug Pradaxa (dabigatran) as an option for treating and preventing recurrent and potentially fatal blood clots in the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism; PE) in adults. 31 October 2014
Generics
US drugmaker The Medicines Company says that the US District Court for the Northern District of Illinois in The Medicines Company v Mylan case entered judgment in favor of TMC on all issues concerning US Patent No 7,582,727. 28 October 2014
Pharmaceutical
In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute for Health and Care Excellence (NICE) has recommended German pharma major Bayer’s Xarelto (rivaroxaban) as an option for preventing blood clots in people who have had a heart attack as a result of a blockage or narrowing in one of the blood vessels in the heart. 23 October 2014
Generics
It is projected that the heparin active pharmaceutical ingredient (API) in China will achieve an additional capacity of more than 20 trillion units by 2015, when China's total capacity will exceed 30 trillion units, accounting for roughly 80% of the global demand, according to a new report. 21 October 2014
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze